Can Destroying Senescent Cells Treat Age-Related Disease? (March 1, 2020)
Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.
Management
Members of UNITY’s management team have collectively advanced over 100 therapeutic candidates into human clinical trials and are responsible for over 10 FDA-approved medicines.
ANIRVAN GHOSH, PH.D.
Chief Executive Officer
JAMIE DANANBERG, M.D.
Chief Medical Officer
LYNNE SULLIVAN
Chief Financial Officer and Head of Corporate Development
PRZEMYSLAW (MIKE) SAPIEHA, PH.D.
Chief Scientific Advisor
SUSAN LUNDEEN
Chief Human Resources Officer
ALEX NGUYEN
General Counsel
NATHAN GUZ, PH.D.
Vice President of Operations
JASON DAMIANO, PH.D.
Vice President of Translational Biology
BOARD OF DIRECTORS
PAUL L. BERNS
Former President and Chief Executive Officer,
Anacor Pharmaceuticals, Inc.
KRISTINA BUROW
Managing Director,
ARCH Venture Partners
GRAHAM COOPER
Former CFO and COO, Assembly Biosciences, Inc.
Former CFO, Receptos, Inc.,
Assembly Biosciences, Inc.
NATHANIEL DAVID, PH.D.
Co-Founder,
UNITY Biotechnology
ANIRVAN GHOSH, PH.D.
Chief Executive Officer,
UNITY Biotechnology
KEITH R. LEONARD JR.
Chairman,
UNITY Biotechnology
GILMORE O’NEILL, M.B.
Chief Medical Officer and Executive
Vice President of R&D,
Sarepta Therapeutics
MARGO ROBERTS, PH.D.
Former Chief Scientific Officer,
Lyell Immunopharma, Inc.
CAMILLE SAMUELS
Partner,
Venrock
Can Destroying Senescent Cells Treat Age-Related Disease? (March 1, 2020)
10 Breakthrough Technologies (February 26, 2020)
